Financial Results Announcement - SenesTech, Inc. will report its second quarter 2025 financial results for the period ended June 30, 2025, after market close on August 7, 2025 [1] - A conference call is scheduled for the same day at 5:00 p.m. Eastern time to review the results [1][2] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, with products like ContraPest®, the only U.S. EPA-registered contraceptive for rats, and Evolve™ products for rodents [4] - The company's mission emphasizes proactive, safe, and sustainable pest management solutions, aiming for clean cities and efficient businesses [4] Webcast and Replay Information - Interested parties can access the live conference call via a webcast available on the company's Investor Relations website [2] - A replay of the webcast will be available for 90 days following the event [3]

Core Points - SenesTech, Inc. announced the closing of the exercise of outstanding warrants to purchase 1,458,872 shares of common stock at an exercise price of $2.90 per share, generating approximately $4.4 million in gross proceeds [1][4] - The company issued new unregistered short-term warrants for the same number of shares at an exercise price of $4.15 per share, with a purchase price of $0.125 per warrant, potentially raising an additional $6.0 million if fully exercised [3][4] - The net proceeds from the transaction are intended for working capital and general corporate purposes [4] Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, having developed products like ContraPest®, the only U.S. EPA-registered contraceptive for rats, and Evolve™ products for rodents [8]

Core Viewpoint - SenesTech, Inc. has entered into definitive agreements for the immediate exercise of outstanding warrants to purchase 1,458,872 shares of common stock at an exercise price of $2.90 per share, with the transaction expected to close around July 1, 2025 [1] Group 1: Warrant Exercise and Financial Details - The company will issue new unregistered short-term warrants to purchase an additional 1,458,872 shares at an exercise price of $4.15 per share, with a purchase price of $0.125 per warrant [3] - The gross proceeds from the exercise of existing warrants are expected to be approximately $4.4 million, while potential gross proceeds from the new short-term warrants could reach approximately $6.0 million if fully exercised [4] - The net proceeds from the transaction are intended for working capital and general corporate purposes [4] Group 2: Regulatory and Compliance Information - The resale of shares from the existing warrants has been registered under an effective registration statement on Form S-3 [5] - The new short-term warrants have not been registered under the Securities Act of 1933, and may not be offered or sold in the U.S. without an effective registration statement or applicable exemption [6] Group 3: Company Overview - SenesTech is focused on humane management of animal pest populations through fertility control, with products like ContraPest® and Evolve™ designed for effective pest management [8]

Core Insights - SenesTech, Inc. has reported successful results from urban deployments of its Evolve™ Rat Birth Control in Hong Kong and San Francisco, demonstrating a faster and more sustainable approach to rodent control by combining fertility control with traditional rodenticides [1][3][5] Group 1: Urban Rodent Challenges - Global cities are facing persistent rodent issues due to dense infrastructure, hard-to-access breeding sites, and abundant food sources, leading to the inadequacy of traditional rodenticide programs over time [2] - Rodents have shown adaptability to poisons, resulting in unchecked reproduction despite aggressive control measures [2] Group 2: Integrated Pest Management Strategy - The integrated strategy employed in Hong Kong involved deploying Evolve's palatable soft bait alongside conventional rodenticide blocks, leading to a significant reduction in rodent sightings and no new litters detected within three months [3][4] - In San Francisco, a similar approach resulted in reduced visible rodent activity, decreased overall poison usage, and a measurable drop in new rodent births [4] Group 3: Industry Implications - The success of these deployments indicates that fertility control can serve as a practical tool for pest professionals, enhancing integrated pest management (IPM) programs and reducing reliance on rodenticides [5] - The company is preparing for a container-sized order from Hong Kong, signaling rapid expansion and increased demand for its products [5] Group 4: Market Opportunities - Fertility control solutions like Evolve align with evolving environmental regulations and public demand for humane, low-toxicity pest management, offering improved outcomes and better ROI for pest control professionals and property owners [6] - This trend indicates a rapidly growing global market for next-generation rodent control solutions that complement traditional methods [6]

Core Insights - SenesTech, Inc. has successfully completed a nine-month field trial of its Evolve™ Rat Birth Control at the University Hills community, marking a significant step in ecologically responsible pest management [1][2][3] - The initiative, driven by resident demand, aimed to eliminate rodenticides in favor of integrated pest management strategies that prioritize environmental safety [2][5] - Evolve was deployed across 267 bait stations, achieving a 98% consumption rate among rats, indicating high acceptance and effectiveness of the bait [3][5] Company Overview - SenesTech specializes in fertility control solutions for managing animal pest populations, with products like ContraPest® and Evolve™ designed to be humane, effective, and sustainable [7] - The company emphasizes its commitment to improving global health through responsible pest management practices [7] Community Engagement - The project involved collaboration with the Irvine Campus Housing Authority and the grassroots initiative HOOT Group, which promotes owl nesting to reduce reliance on rodenticides [4][5] - The community's transition away from rodenticides has led to reduced rodent complaints and less observed rodent activity [5] Future Plans - SenesTech is placing a multi-pallet restocking order for continued deployment and expansion of its products [6]

Core Insights - SenesTech has entered a distribution agreement with Bradley Caldwell, Inc. to enhance the availability of Evolve™ Rodent Birth Control in rural America [1][2] - The partnership aims to leverage BCI's extensive network of over 8,000 dealers to improve access to rodent control solutions in agricultural communities [1][2] - This agreement represents a significant step in SenesTech's commercialization strategy, with BCI's initial order being the largest distributor stocking order received by the company [3] Company Overview - SenesTech specializes in fertility control for managing animal pest populations, with products like ContraPest and Evolve designed to be humane and effective [4] - The company focuses on providing sustainable pest management solutions that integrate into existing pest management programs [4] Strategic Benefits - The partnership with BCI is expected to accelerate market penetration in underserved areas where traditional rodenticides face challenges [7] - BCI customers will gain a competitive edge by offering a scientifically-backed, humane alternative to traditional poisons [7] - The collaboration supports SenesTech's long-term growth strategy, anticipating revenue increases from expanded retail sales and new customer acquisition [7]

Summary of SenesTech (SNES) 2025 Conference Call Company Overview - **Company**: SenesTech, a biotech and life sciences company focused on rodent control through reproductive management rather than lethal methods [5][6] - **Ticker Symbol**: SNES, traded on NASDAQ [4] Core Product and Market Strategy - **Flagship Product**: Evolve, launched in 2024, is a soft bait designed for rodent fertility control, which has quickly become the top-selling product [12][14] - **Sales Growth**: Evolve sales grew by 40% year-over-year in Q1 2025 [15][37] - **Market Opportunity**: The U.S. rodenticide market is estimated at $1 billion annually, with a global market of $4.5 billion [34] Unique Selling Proposition - **Sustainable Approach**: Focus on controlling the birth rate of rodents rather than relying on poisons, which have social, political, and ecological drawbacks [6][8][30] - **Product Safety**: Evolve is designated as a minimum risk product by the EPA, using cottonseed oil as the active ingredient, making it safer for pets and wildlife [14][16] Distribution Channels - **Six Channel Strategy**: Includes e-commerce, agriculture distributors, pest management distributors, retail (e.g., Ace Hardware), international distributors, and direct sales to large customers [18][19] - **E-commerce Growth**: E-commerce sales increased by over 7%, with a run rate approaching $60,000 to $70,000 per month [20][21] Municipal and International Opportunities - **Municipal Deployments**: Significant projects in Chicago and New York City, with repeat orders indicating product effectiveness [23][24][25] - **International Expansion**: Exclusive distribution agreements signed in 12 countries, with expected approvals in Australia and New Zealand [27][28] Financial Performance - **Revenue Growth**: Record revenue of $1.9 million in 2024, up 56% from the previous year [39] - **Gross Margin Improvement**: Gross margins for Evolve reached 64%, compared to 32% in Q1 of the previous year [40] - **Cost Optimization**: Initiatives to reduce operating costs include pausing new product development and optimizing sales efforts [44] Future Outlook - **Path to Profitability**: Aiming for cash flow breakeven at approximately $1.5 million per quarter, with current revenues around $500,000 per quarter [45][46] - **Market Trends**: Increasing awareness of the need for humane rodent control solutions due to public health concerns and regulatory changes [52][53] Key Takeaways - **Transformative Opportunity**: SenesTech believes it has a paradigm-changing product that addresses long-standing rodent control issues in a sustainable manner [55][56] - **Execution Strategy**: Focus on expanding market presence, improving product offerings, and enhancing operational efficiencies to drive future growth [54][56]

Company Participation - SenesTech, Inc. will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 [1] - The webcast presentation is scheduled for 3:30 p.m. ET and will be accessible via the conference home page or directly through a provided link [2] - Management will engage in virtual one-on-one meetings throughout the event, with arrangements available through Lytham Partners [3] Company Overview - SenesTech is focused on improving global health by managing animal pest populations through fertility control solutions [4] - The company developed ContraPest, the only U.S. EPA-registered contraceptive for male and female rats, along with Evolve and Evolve Mouse, which are EPA-designated minimum risk contraceptives for rodents [4] - SenesTech aims to integrate its products into pest management programs to enhance effectiveness and promote humane, safe, and sustainable pest control [4]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $485,000, an increase of 17% from Q1 2024 [17] - EVOLVE revenue grew by 40% and accounted for 79% of total sales, while ContraPest revenue decreased by approximately 40% [17] - Gross margins increased to 64.5% compared to 32.5% in Q1 2024, with gross profit rising by 132% to $313,000 [20][21] Business Line Data and Key Metrics Changes - EVOLVE product line significantly contributed to revenue growth, with e-commerce sales increasing by 107% [10][18] - Municipal sales saw a sevenfold increase compared to the previous year, driven by new deployments in major cities [19] - ContraPest, while deemphasized, still retains a loyal customer base and is expected to continue generating revenue [17] Market Data and Key Metrics Changes - E-commerce accounted for 61% of overall Q1 sales, with Amazon being the predominant channel [18] - International sales were not recognized in Q1 but are anticipated to grow with pending regulatory approvals in various markets [19][12] Company Strategy and Development Direction - The company is focusing on expanding the EVOLVE product line and enhancing operational efficiencies to achieve profitability [15][25] - Strategic initiatives have been implemented to reduce expenses by $2 million annually, which should improve financial performance in upcoming quarters [15][22] - The company aims to penetrate various markets, including agriculture, zoos, and residential applications, to drive future growth [27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for significant growth in municipal applications and other markets [26] - The company is on a pathway to profitability, with a reduced revenue threshold for cash flow breakeven set at $1.5 million quarterly [16][22] - There is a clear focus on executing strategies effectively while maintaining efficiency [25] Other Important Information - The company completed a strategic financing during Q1, raising $1 million and issuing $4 million in short-term warrants [23] - The new larger facility in Phoenix is expected to support increasing demand without significantly raising costs [21] Q&A Session Summary - No questions were asked during the Q&A session, leading to a conclusion of the call [29]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $485,000, an increase of 17% from Q1 2024 [17] - EVOLVE revenue grew by 40% and accounted for 79% of total sales, while ContraPest revenue decreased by approximately 40% [17] - Gross margins increased to 64.5% compared to 32.5% in Q1 2024, with gross profit rising by 132% to $313,000 [20][21] Business Line Data and Key Metrics Changes - EVOLVE product line is driving growth, with significant revenue contributions from e-commerce, which accounted for 61% of total sales and increased by 107% year-over-year [18] - Municipal sales saw a sevenfold increase compared to the previous year, driven by new deployments in major cities [19] - ContraPest continues to have loyal customers, but its sales are being deemphasized as the company focuses on EVOLVE [17] Market Data and Key Metrics Changes - E-commerce sales have expanded to platforms like Amazon, Walmart, and Tractor Supply, contributing significantly to revenue growth [10] - International operations are expected to grow, with agreements signed in 12 countries, including Indonesia and the Philippines [12] - No international sales were recognized in Q1, but potential significant orders are pending regulatory approval [19] Company Strategy and Development Direction - The company is focusing on expanding the EVOLVE product line and improving operational efficiencies to achieve profitability [15][25] - Strategic initiatives have been implemented to reduce expenses by $2 million annually, which will help lower the revenue threshold for cash flow breakeven to $1.5 million quarterly [15][22] - The company aims to revolutionize pest control, particularly in municipal applications, agriculture, and commercial sectors [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the growth potential in municipal deployments and e-commerce, anticipating continued success in these areas [10][11] - The company is focused on executing its strategy effectively to capitalize on market opportunities and achieve profitability [25][28] - Management highlighted the importance of operational optimization and the potential for significant revenue growth from new markets [25][26] Other Important Information - The company completed a strategic financing that raised $1 million and included short-term warrants, providing additional capital without significant dilution [23] - The company has moved into a larger facility to meet increasing demand without dramatically increasing costs [21] Q&A Session Summary - No questions were asked during the Q&A session, and the call concluded without further inquiries [29]